Personalized Microbiome Modulation to Improve Clinical Outcomes in Pediatric Inflammatory Bowel Disease

Microorganisms (MDPI), 2025
https://www.mdpi.com/2076-2607/13/5/1047

Design	Multi-omics interventional study in paediatric IBD.
Measurements	Metagenomics, metabolomics, transcriptomics and clinical biomarkers.
Intervention	Dietary intervention and probiotic/synbiotic supplementation.
Reported outcome	Identification of dysbiosis patterns and therapeutic targets; clinical outcomes as published.

Scope of this document

This is a one-page orientation to the study design and reported outcomes. It is not a substitute for the publication. Full eligibility criteria, endpoint definitions, assay methods, statistical analysis, confidence intervals, ethics approval, funding and declared conflicts of interest are given in the peer-reviewed paper linked above.

Limitations that apply to this study

The study is not a randomised controlled trial. Without a control arm, placebo response, regression to the mean and selection effects cannot be separated from the intervention effect. Patient-reported outcomes are subjective. Results describe the population studied and should not be extrapolated beyond it.

Requests for analysis-level data or a protocol review: research@nostrabiome.ai

Methodology questions are answered at nostrabiome.ai/research-faq